Creative Planning Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Creative Planning acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,002 shares of the company's stock, valued at approximately $362,000.

Other hedge funds also recently made changes to their positions in the company. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after buying an additional 1,530 shares in the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at $223,000. Finally, SG Americas Securities LLC raised its stake in shares of Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after buying an additional 3,379 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS traded up $2.63 during mid-day trading on Friday, reaching $49.42. 1,037,481 shares of the company were exchanged, compared to its average volume of 725,116. Tarsus Pharmaceuticals, Inc. has a 12 month low of $15.47 and a 12 month high of $51.59. The company has a fifty day moving average of $35.50 and a 200 day moving average of $31.90. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.88 billion, a PE ratio of -10.82 and a beta of 1.00.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million for the quarter, compared to analyst estimates of $31.30 million. During the same quarter in the prior year, the firm earned ($1.17) EPS. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TARS. William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Oppenheimer reiterated an "outperform" rating and set a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $51.60.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.